Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 3, 2015, Pages 390-397

  Ay, C ^a   Posch, F ^a   Kaider, A ^a   Zielinski, C ^a   Pabinger, I ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bias; Neoplasms; Risk; Thrombosis; Venous thromboembolism

Indexed keywords

BIOLOGICAL MARKER; D DIMER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; FOLLOW UP; HAZARD ASSESSMENT; HAZARD RATIO; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; PANCREAS CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SURVIVAL RATE; VENOUS THROMBOEMBOLISM; AUSTRIA; BLOOD; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; MORTALITY; NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICAL BIAS; TIME FACTOR;

AUSTRIA; BIAS (EPIDEMIOLOGY); BIOMARKERS; CHI-SQUARE DISTRIBUTION; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84923821726     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12825     Document Type: Article

References (13)

1. Khorana AA. Cancer and coagulation. Am J Hematol 2012; 87(Suppl. 1): S82-7.
2. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.
3. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116: 5377-82.
4. Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, Quehenberger P, Wagner O, Zielinski C, Pabinger I. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27: 4124-9.
5. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
6. Parpia S, Julian JA, Thabane L, Lee AY, Rickles FR, Levine MN. Competing events in patients with malignant disease who are at risk for recurrent venous thromboembolism. Contemp Clin Trials 2011; 32: 829-33.
7. Campigotto F, Neuberg D, Zwicker JI. Biased estimation of thrombosis rates in cancer studies using the method of Kaplan and Meier. J Thromb Haemost 2012; 10: 1449-51.
8. Campigotto F, Neuberg D, Zwicker JI. Accounting for death as a competing risk in cancer-associated thrombosis studies. Thromb Res 2012; 129(Suppl. 1): S85-7.
9. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366: 601-9.
10. Coviello VBM. Cumulative incidence estimation in the presence of competing risks. Stata J 2004; 4: 103-12.
11. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc 1999; 94: 496-509.
12. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007; 13: 559-65.
13. Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, Zielinski C, Pabinger I. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica 2012; 97: 1158-64.